AI assistant
Sending…
Spyre Therapeutics, Inc. — Director's Dealing 2021
Jul 8, 2021
32226_dirs_2021-07-08_e00e9f66-aace-4a14-b7b3-350fce8c4c79.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-07-06
Reporting Person: Alspaugh Jonathan (Chief Financial Officer)
More from Spyre Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Regulatory Filings
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
Apr 16
Capital/Financing Update
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27